Vorinostat
- Generic Name
- Vorinostat
- Brand Names
- Zolinza
- Drug Type
- Small Molecule
- Chemical Formula
- C14H20N2O3
- CAS Number
- 149647-78-9
- Unique Ingredient Identifier
- 58IFB293JI
- Background
Vorinostat (rINN) or suberoylanilide hydroxamic acid (SAHA), is a drug currently under investigation for the treatment of cutaneous T cell lymphoma (CTCL), a type of skin cancer, to be used when the disease persists, gets worse, or comes back during or after treatment with other medicines. It is the first in a new class of agents known as histone deacetylase...
- Indication
用于治疗加重、持续和复发或用两种全身性药物治疗后无效的T细胞淋巴瘤(CTCL, 一种非霍奇金淋巴瘤)。
- Associated Conditions
- Cutaneous T-Cell Lymphoma Recurrent, Persistent Cutaneous T-Cell Lymphoma, Progressive Cutaneous T-cell lymphoma
- Associated Therapies
- -
Study of Carfilzomib and Vorinostat for Relapsed or Refractory Lymphoma
- First Posted Date
- 2011-01-13
- Last Posted Date
- 2015-12-03
- Lead Sponsor
- University of Rochester
- Target Recruit Count
- 20
- Registration Number
- NCT01276717
- Locations
- 🇺🇸
University of Rochester, Rochester, New York, United States
🇺🇸Virginia Commonwealth University Massey Cancer Center, Richmond, Virginia, United States
Capecitabine and Vorinostat in Treating Patients With Recurrent and/or Metastatic Head and Neck Cancer
- Conditions
- Stage IVA Oral Cavity Squamous Cell CarcinomaRecurrent Laryngeal Squamous Cell CarcinomaStage IVA Laryngeal Squamous Cell CarcinomaStage IVC Oropharyngeal Squamous Cell CarcinomaRecurrent Hypopharyngeal Squamous Cell CarcinomaStage IVA Oropharyngeal Squamous Cell CarcinomaStage IVB Hypopharyngeal Squamous Cell CarcinomaStage IVB Laryngeal Squamous Cell CarcinomaStage IVB Oral Cavity Squamous Cell CarcinomaStage IVB Oropharyngeal Squamous Cell Carcinoma
- Interventions
- First Posted Date
- 2010-12-28
- Last Posted Date
- 2017-04-14
- Lead Sponsor
- National Cancer Institute (NCI)
- Target Recruit Count
- 25
- Registration Number
- NCT01267240
- Locations
- 🇺🇸
Tower Cancer Research Foundation, Beverly Hills, California, United States
🇺🇸City of Hope Comprehensive Cancer Center, Duarte, California, United States
🇺🇸USC / Norris Comprehensive Cancer Center, Los Angeles, California, United States
Sirolimus or Vorinostat and Hydroxychloroquine in Advanced Cancer
- Conditions
- Interventions
- First Posted Date
- 2010-12-24
- Last Posted Date
- 2021-03-04
- Lead Sponsor
- M.D. Anderson Cancer Center
- Target Recruit Count
- 143
- Registration Number
- NCT01266057
- Locations
- 🇺🇸
University of Texas MD Anderson Cancer Center, Houston, Texas, United States
Phase I/II Adaptive Randomized Trial of Bevacizumab Versus Bevacizumab Plus Vorinostat in Adults With Recurrent Glioblastoma
- Conditions
- Interventions
- First Posted Date
- 2010-12-24
- Last Posted Date
- 2018-07-31
- Lead Sponsor
- National Cancer Institute (NCI)
- Target Recruit Count
- 96
- Registration Number
- NCT01266031
- Locations
- 🇺🇸
Baylor University Medical Center, Dallas, Texas, United States
Paclitaxel and Carboplatin in Treating Patients With Metastatic or Recurrent Solid Tumors and HIV Infection
- Conditions
- Recurrent Breast CancerRecurrent Squamous Cell Carcinoma of the LarynxRecurrent Squamous Cell Carcinoma of the NasopharynxSalivary Gland Squamous Cell CarcinomaStage IV Anal CancerStage IV Non-small Cell Lung CancerStage IV Squamous Cell Carcinoma of the LarynxStage IV Squamous Cell Carcinoma of the NasopharynxUnspecified Adult Solid Tumor, Protocol SpecificHIV Infection
- Interventions
- First Posted Date
- 2010-11-29
- Last Posted Date
- 2020-07-29
- Lead Sponsor
- AIDS Malignancy Consortium
- Target Recruit Count
- 17
- Registration Number
- NCT01249443
- Locations
- 🇺🇸
UCLA Center for Clinical AIDS Research and Education, Los Angeles, California, United States
🇺🇸Pennsylvania Oncology Hematology Associates, Philadelphia, Pennsylvania, United States
🇺🇸UC San Diego Moores Cancer Center, La Jolla, California, United States
Vorinostat, Temozolomide, or Bevacizumab in Combination With Radiation Therapy Followed by Bevacizumab and Temozolomide in Young Patients With Newly Diagnosed High-Grade Glioma
- First Posted Date
- 2010-11-07
- Last Posted Date
- 2024-02-20
- Lead Sponsor
- National Cancer Institute (NCI)
- Target Recruit Count
- 101
- Registration Number
- NCT01236560
- Locations
- 🇺🇸
Mattel Children's Hospital UCLA, Los Angeles, California, United States
🇺🇸Naval Medical Center - Portsmouth, Portsmouth, Virginia, United States
🇺🇸Children's Oncology Group, Philadelphia, Pennsylvania, United States
Vorinostat and Isotretinoin in Treating Patients With High-Risk Refractory or Recurrent Neuroblastoma
- First Posted Date
- 2010-09-24
- Last Posted Date
- 2015-11-24
- Lead Sponsor
- National Cancer Institute (NCI)
- Target Recruit Count
- 29
- Registration Number
- NCT01208454
- Locations
- 🇺🇸
Children's Hospital Los Angeles, Los Angeles, California, United States
🇺🇸Children's Healthcare of Atlanta - Egleston, Atlanta, Georgia, United States
🇺🇸Boston Children's Hospital, Boston, Massachusetts, United States
Vorinostat and Combination Chemotherapy With Rituximab in Treating Patients With HIV-Related Diffuse Large B-Cell Non-Hodgkin Lymphoma or Other Aggressive B-Cell Lymphomas
- Conditions
- Ann Arbor Stage I Grade 3 Follicular LymphomaAnn Arbor Stage II Diffuse Large B-Cell LymphomaAnn Arbor Stage II Grade 3 Contiguous Follicular LymphomaAIDS-Related Plasmablastic LymphomaAIDS-Related Primary Effusion LymphomaAnn Arbor Stage I Diffuse Large B-Cell LymphomaAnn Arbor Stage II Grade 3 Non-Contiguous Follicular LymphomaAnn Arbor Stage III Diffuse Large B-Cell LymphomaAnn Arbor Stage III Grade 3 Follicular LymphomaAnn Arbor Stage IV Diffuse Large B-Cell Lymphoma
- Interventions
- First Posted Date
- 2010-09-02
- Last Posted Date
- 2023-11-21
- Lead Sponsor
- National Cancer Institute (NCI)
- Target Recruit Count
- 107
- Registration Number
- NCT01193842
- Locations
- 🇺🇸
UCLA / Jonsson Comprehensive Cancer Center, Los Angeles, California, United States
🇺🇸Northwestern University, Chicago, Illinois, United States
🇺🇸Ohio State University Comprehensive Cancer Center, Columbus, Ohio, United States
Vorinostat and Radiation Therapy Followed by Maintenance Therapy With Vorinostat in Treating Younger Patients With Newly Diagnosed Diffuse Intrinsic Pontine Glioma
- First Posted Date
- 2010-08-26
- Last Posted Date
- 2021-10-28
- Lead Sponsor
- National Cancer Institute (NCI)
- Target Recruit Count
- 79
- Registration Number
- NCT01189266
- Locations
- 🇺🇸
Valley Children's Hospital, Madera, California, United States
🇺🇸Children's Hospital of Philadelphia, Philadelphia, Pennsylvania, United States
🇺🇸Cedars Sinai Medical Center, Los Angeles, California, United States
Low-dose (12 Gy) TSEBT+Vorinostat Versus Low-dose TSEBT Monotherapy in Mycosis Fungoides
- Conditions
- Interventions
- First Posted Date
- 2010-08-24
- Last Posted Date
- 2017-11-20
- Lead Sponsor
- Stanford University
- Target Recruit Count
- 28
- Registration Number
- NCT01187446
- Locations
- 🇺🇸
MD Anderson Cancer Center, Houston, Texas, United States
🇺🇸Stanford University School of Medicine, Stanford, California, United States
🇺🇸Yale University School of Medicine, New Haven, Connecticut, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.